ABSTRACT
The aim of this study was the evaluation of the discomfort level during the utilization of non oclusal intraoral appliance during sleep in patients with muscular temporomandibular dysfunction; time of acceptance; and the effectiveness of non oclusal intraoral appliance related to the relief of pain symptoms. We evaluated 30 patients from Orofacial Pain and Temporomandibular Dysfunction Clinic (UNIFESP/EPM/HSP) with muscular temporamandibular dysfunction, 25 females and 5 males, between 19 to 60 years. We used a non-oclusal intraoral appliance, based on the model developed by Minagi et al. (2001). Patients was conducted to use the appliance during all sleeping period e to persist in use, even when there was any kind of discomfort, which would be natural during the adaptation period, for 30 consecutive days. After this period, the researcher interviewed all patients, answering specific questions designed for this study. The mean time for adaptation was 4 days. Of all patients, 23.33 percent had no difficulty in adapting the appliance, with immediate acceptance. The gradual reduction in the intensity of myofascial pain and discomfort, as well as improving the quality of life in 78.3 percent of the sample confirmed the effectiveness of non-oclusal palatal intraoral appliance without occlusal contact in relieving the painful symptoms of muscular TMD.
El objetivo fue evaluar la respuesta al uso de un aparato intraoral no oclusal durante el sueño en pacientes con disfunción temporomandibular (DTM) muscular. Se evaluaron 30 pacientes de la Clínica de Dolor Orofacial y Disfunción Temporomandibular (UNIFESP/EPM/HSP) con diagnóstico de DTM muscular, 25 mujeres y 5 hombres, entre 19 y 60 años. Se utilizó un aparato intraoral no oclusal, basado en el modelo desarrollado por Minagi et al. (2001) y se evaluó el tiempo de adaptación al aparato y la eficacia en términos de reducción del dolor. Los pacientes utilizaron el aparato al acostarse y mientras dormían por 30 días contínuos. Después de este período, todos los pacientes fueron entrevistados. El tiempo medio para la adaptación fue de 4 días. De todos los pacientes, el 23,33 por ciento no tuvo ninguna dificultad de adaptación al aparato, con aceptación inmediata. La reducción gradual en la intensidad del dolor miofascial y el malestar, así como la mejora de la calidad de vida en el 78,3 por ciento de la muestra confirmó la eficacia del aparato intraoral para aliviar los síntomas dolorosos de DTM muscular.
Subject(s)
Humans , Male , Adult , Female , Young Adult , Middle Aged , Facial Pain/etiology , Facial Pain/prevention & control , Orthodontic Appliances , Temporomandibular Joint Disorders/complications , Temporomandibular Joint Disorders/therapy , Adaptation to Disasters , Patient Satisfaction , Surveys and Questionnaires , Time FactorsABSTRACT
The purpose of this study was to investigate if botulinum neurotoxin type-A (BoNT/A) had a preemptive antinociceptive effect in a formalin-induced orofacial pain model (FT). To test this hypothesis, male Rattus norvegicus were injected with isotonic saline solution 0.9 percent or BoNT/A administered as a 40 μl bolus, lateral to their nose, at 24 hours, 8, 15, 22, 29 or 36 days pre-FT. The procedures were repeated 42 days later. Influence on motor activity was assessed through the open-field test. Pain scores corresponded to the time spent rubbing and flicking the injected area. Animals pre-treated with BoNT/A at the first protocol (8 days subgroup) showed reduced inflammatory scores (p=0.011). For the other groups no significant results were observed at any phase. Motor activity was similar in both groups. BoNT/A showed to be effective preventing inflammatory pain up to eight days after the first treatment, an effect not reproduced on the second dose administration.
O objetivo deste estudo foi investigar o efeito preemptivo da neurotoxina botulínica do tipo/A (NTBo/A) através de um modelo de dor orofacial induzida pelo teste da formalina (TF). Rattus norvegicus machos foram injetados no lábio superior com solução salina isotônica 0,9 por cento (SSI) ou NTBo/A (subgrupos 24 horas, 8, 15, 22, 29 ou 36 dias) antes do TF, em dois tratamentos farmacológicos e respectivas avaliações intercalados por 42 dias. Os escores da dor corresponderam ao tempo de fricção da região injetada. Após o primeiro pré-tratamento com NTBo/A no subgrupo 8 dias os escores da fase inflamatória foram menores do que no grupo SSI (p=0,011). Todas as outras comparações não foram significativas. Nos testes de atividade motora não ocorreram diferenças entre SSI e NTBo/A. A NTBo/A pode ser considerada como tratamento preemptivo das dores orofaciais quando utilizada até oito dias antes do estímulo álgico, não havendo consistência terapêutica após um segundo tratamento.